A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients with Metastatic Breast Cancer (mBCA) Who Have Progressed Through PriorHormonal Therapy
Study of Imprime PGG and Pembrolizumab (Keytruda) in Patients with Metastatic Breast Cancer (mBCA)
Sponsor: HiberCell, Inc
Enrolling: Male and Female Patients
IRB Number: AAAU0813
U.S. Govt. ID: NCT05159778
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out, good and/or bad, the effects of the investigational drug, Imprime PGG, when given together with pembrolizumab (also known as Keytruda, a type of checkpoint inhibitor) in the treatment of your type of cancer. Checkpoint inhibitors are a type of immunotherapy that block immune checkpoint proteins from binding with partner proteins. An investigational drug (study drug) is one that is not approved by the United States Food and Drug Administration (FDA). Imprime PGG is a glucan. Glucans are molecules that are not normally present in your body. Imprime PGG when given with pembrolizumab may help the immune system to better fight your type of cancer. Pembrolizumab is already approved by the FDA when given alone or in combination with other treatments for many types of cancer including, but not limited to melanoma; lung cancers; head and neck cancer; gastric, esophageal, and liver cancers; several types of blood cancer; and Triple Negative Breast Cancer (TNBC). The combination of these drugs used in this study is investigational. This combination has not been approved by the FDA and neither pembrolizumab nor Imprime PGG are approved therapies for hormone receptor-positive breast cancer.
This study is closed
Julia McGuinness, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with metastatic breast cancer (mBCA)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator